公告称，QX004N最近已进入III期临床试验，成为公司管线中第四个成功进入III期阶段的产品。 最近，公司已收到翰森制药根据授权协议支付的PsIII期里程碑及其他付款，共计人民币5800万元。 荃信生物-B(02509)公布，公司正在开发用于治疗银屑病(Ps)及克罗恩病(CD)的白介素23p19亚基 (IL23p19)抑制剂QX004N。于2024年4月，公司与翰森制药集团有限公司(03692.HK)的全资附属公司翰 森(上海)健康科技有限公司就QX004N在中国内地、中国台湾、中国香港及中国澳门的研发、生产及商 业化订立独家对外授权协议。 ...

Core Viewpoint - The company is developing an IL23p19 inhibitor, QX004N, for the treatment of psoriasis and Crohn's disease, and has entered into an exclusive licensing agreement with Hansoh Pharmaceutical for its development and commercialization in several regions [1] Group 1 - QX004N has recently entered Phase III clinical trials, marking it as the fourth product in the company's pipeline to reach this stage [1] - The company has received a total of RMB 58 million from Hansoh Pharmaceutical as milestone and other payments related to the Phase III trial [1]

Core Insights - The company is developing an IL23p19 inhibitor QX004N for the treatment of psoriasis (Ps) and Crohn's disease (CD) [1] - QX004N has recently entered Phase III clinical trials, marking it as the fourth product in the company's pipeline to reach this stage [1] - The company has signed an exclusive licensing agreement with Hansoh Pharmaceutical Group Co., Ltd. for the R&D, production, and commercialization of QX004N in mainland China, Taiwan, Hong Kong, and Macau [1] - The company received a total of RMB 58.0 million from Hansoh Pharmaceutical as milestone and other payments related to the Phase III trial of Ps [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Qyuns Therapeutics Co., Ltd. 江蘇荃信生物醫藥股份有限公司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2509） 自願公告 QX004N進 入III期臨床試驗及 收到翰森製藥的付款 本 公 告 乃 由 江 蘇 荃 信 生 物 醫 藥 股 份 有 限 公 司（「本公司」）自 願 刊 發，以 向 股 東 及 潛 在投資者提供本公司最新的業務發展狀況。 本 公 司 正 在 開 發 用 於 治 療 銀 屑 病（「Ps」）及 克 羅 恩 病（「CD」）的 白 介 素23p19亞 基（「IL- 23p19」）抑制劑QX004N。於2024年4月，本公司與翰森製藥集團有限公司（「翰森製藥」， 股 份 代 號：3692.HK）的 全 資 附 屬 公 司 翰 森（上 海）健 康 科 ...

格隆汇8月5日丨荃信生物-B(02509.HK)公布，公司董事会会议将于2025年8月15日（星期五）举行，藉 以（其中包括）考虑及批准集团截至2025年6月30日止的六个月中期业绩及其发布，考虑建议派发中期 股息（如有），以及处理其他事项。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Qyuns Therapeutics Co., Ltd. 江蘇荃信生物醫藥股份有限公司（「本公司」）連 同其附屬公司統稱（「本集團」）董 事 會（「董事會」）謹此公佈，本公司董事會會議將於2025年8月15日（星期五）舉行，藉以（其 中包括）考慮及批准本集團截至2025年6月30日 止 的 六 個 月 中 期 業 績 及 其 發 佈，考 慮建議派發中期股息（如 有），以及處理其他事項。 承董事會命 江蘇荃信生物醫藥股份有限公司 董事會主席及執行董事 裘霽宛先生 香港，2025年8月5日 於 本 公 告 日 期，本 公 司 董 事 會 成 員 包 括 主 席 及 執 行 董 事 裘 霽 宛 先 生、執 行 董 事 吳 亦 亮 先 生 及 林 偉 棟 先 生、非 執 行 董 事 余 熹 先 生 及 吳 志 強 先 生 以 及 獨 立 非 執 行 董 ...

Group 1 - The stock price of Zai Lab Limited (02509) has increased by over 8%, reaching a high of 22.15 HKD, the highest since October of last year, with a nearly 40% increase in the past month [1] - As of the latest update, the stock is up 5.42%, trading at 21.4 HKD with a trading volume of 5.7078 million HKD [1] - Zai Lab is a biopharmaceutical company focused on therapies for autoimmune and allergic diseases, with a fully self-developed drug pipeline and mature commercial-scale production capabilities [1] Group 2 - Zai Lab has a diverse product pipeline with multiple innovative candidates, including one approved product, two in Phase III clinical trials, and four in Phase II and I trials, targeting diseases such as psoriasis, atopic dermatitis, ankylosing spondylitis, systemic lupus erythematosus, asthma, and inflammatory bowel disease [1] - In April, Zai Lab signed a licensing agreement with Caldera Therapeutics for its clinical-stage long-acting dual antibody QX030N, granting Caldera global exclusive rights for development and commercialization [2] - The agreement includes a one-time upfront payment of 10 million USD, approximately 24.88% equity in Caldera, and potential additional payments up to 545 million USD under specific conditions, along with tiered royalties on net sales [2] - Zai Lab's product Selinexor has entered the medical insurance directory, with projected sales of 300 million CNY in 2025 and peak sales estimated between 1.5 billion to 2 billion CNY, contributing to the company's revenue through profit-sharing [2]

Group 1 - The stock of Qianxin Biopharmaceuticals-B (02509) rose over 8% during trading, reaching a new high of 22.15 HKD, with a cumulative increase of nearly 40% in the past month [1] - Qianxin Biopharmaceuticals focuses on biopharmaceutical therapies for autoimmune and allergic diseases, with a fully self-developed drug pipeline and mature commercial-scale production capabilities [1] - The company has a diverse product pipeline, including one product approved for market, two in Phase III clinical trials, and four in Phase II and I trials, targeting diseases such as psoriasis, atopic dermatitis, ankylosing spondylitis, systemic lupus erythematosus, asthma, and inflammatory bowel disease [1] Group 2 - In April, Qianxin Biopharmaceuticals signed a licensing agreement with Caldera Therapeutics for its long-acting dual antibody QX030N, granting Caldera global exclusive rights for development and commercialization [2] - The agreement provided Qianxin Biopharmaceuticals with a one-time payment of 10 million USD, approximately 24.88% equity in Caldera, and potential additional payments up to 545 million USD under specific conditions, along with tiered royalties on net sales [2] - The company expects significant revenue from its biosimilar product, Sailixin, which has entered the medical insurance directory, with projected sales of 300 million RMB in 2025 and peak sales of 1.5 billion to 2 billion RMB [2]

Group 1 - The stock price of Qianxin Biopharmaceuticals-B (02509) has risen over 8% during trading, reaching a new high of 22.15 HKD, marking a nearly 40% increase in the past month [1] - Qianxin Biopharmaceuticals focuses on biopharmaceuticals for autoimmune and allergic diseases, with a fully self-developed drug pipeline and mature commercial-scale production capabilities [1] - The company has a diverse product pipeline, including one product approved for market, two in Phase III clinical trials, and four in Phase II and I trials, targeting diseases such as psoriasis, atopic dermatitis, ankylosing spondylitis, systemic lupus erythematosus, asthma, and inflammatory bowel disease [1] Group 2 - In April, Qianxin Biopharmaceuticals signed a licensing agreement with Caldera Therapeutics for its clinical-stage long-acting dual antibody QX030N, granting Caldera global exclusive rights for development and commercialization [2] - The agreement includes a one-time payment of 10 million USD, approximately 24.88% equity in Caldera, and potential additional payments up to 545 million USD along with tiered royalties on net sales [2] - The company anticipates that its biosimilar product, Sailixin, will enter the medical insurance directory in 2024, with projected sales of 300 million CNY in 2025 and peak sales of 1.5 billion to 2 billion CNY, contributing to the company's revenue through profit sharing [2]

Group 1 - Hong Kong biopharmaceutical stocks have strengthened again, with Lepu Biopharma (02157.HK) and Genscript Biotech (01672.HK) both rising by 9% [1] - Other companies such as Kintor Pharmaceutical (01167.HK) and Qianxin Biopharma (02509.HK) have seen increases of over 7% [1]